Rhumbline Advisers increased its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 29.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,946 shares of the medical research company’s stock after purchasing an additional 12,797 shares during the quarter. Rhumbline Advisers owned approximately 0.09% of PRA Health Sciences worth $4,338,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in PRAH. Dimensional Fund Advisors LP increased its position in shares of PRA Health Sciences by 61.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 295,974 shares of the medical research company’s stock worth $19,306,000 after purchasing an additional 113,074 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of PRA Health Sciences during the 2nd quarter worth about $233,000. Strs Ohio increased its position in shares of PRA Health Sciences by 17.8% during the 2nd quarter. Strs Ohio now owns 18,500 shares of the medical research company’s stock worth $1,387,000 after purchasing an additional 2,800 shares in the last quarter. CAPROCK Group Inc. acquired a new stake in shares of PRA Health Sciences during the 2nd quarter worth about $208,000. Finally, Sei Investments Co. increased its position in PRA Health Sciences by 4.9% in the 2nd quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock valued at $1,100,000 after acquiring an additional 690 shares in the last quarter. Institutional investors and hedge funds own 98.49% of the company’s stock.
In other news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by insiders.
Shares of PRA Health Sciences, Inc. (PRAH) opened at $80.50 on Tuesday. PRA Health Sciences, Inc. has a 1 year low of $52.60 and a 1 year high of $84.38. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. The company has a market cap of $5,186.81, a P/E ratio of 30.09, a PEG ratio of 1.42 and a beta of 0.40.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter in the previous year, the company earned $0.64 EPS. PRA Health Sciences’s revenue was up 23.7% on a year-over-year basis. research analysts expect that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current year.
Several equities research analysts have weighed in on the stock. Raymond James Financial assumed coverage on shares of PRA Health Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $89.00 price objective for the company. SunTrust Banks restated a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday, August 9th. Robert W. Baird raised their price objective on shares of PRA Health Sciences from $82.00 to $83.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, Credit Suisse Group raised their price objective on shares of PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $89.09.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/rhumbline-advisers-has-4-34-million-stake-in-pra-health-sciences-inc-prah.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.